Medivir AB Announces Phase III Data for Simeprevir Demonstrating Efficacy and Safety in Genotype 1 Hepatitis C Patients

STOCKHOLM--(BUSINESS WIRE)--Regulatory News:

Simeprevir achieved SVR12 rates (viral cure) of 79% to 81% in the three pivotal phase III trials QUEST-1, QUEST-2 and PROMISE in genotype 1 hepatitis C patients.

The overall results demonstrate that simeprevir is safe and well tolerated with a safety profile of the simeprevir treatment arms similar to the placebo control.

A majority of the patients, 85-93%, were able to stop all treatment after 24 weeks.

Medivir AB (OMX: MVIR) today announced top-line results from three pivotal phase III trials examining the one pill, once-daily, investigational protease inhibitor, simeprevir (TMC435), administered with pegylated interferon and ribavirin.